2021 Targeted Therapies of Lung Cancer (TTLC) Meeting - Posters-P10. The Frequency of KRAS Mutations in Brazilian Lung Cancer Patients

Pdf Summary

A study conducted in Brazil aimed to assess the frequency of KRAS mutations in non-small cell lung cancer (NSCLC) patients. Targeted therapies have significantly improved the management of NSCLC, but these treatments are only effective for patients with specific mutations. KRAS mutations are found in about 25% of NSCLC cases, but until recently, no targeted therapy was available for these mutations. The study focused on the p.Gly12Cys mutation of KRAS, as a new agent called Sotorasib has shown promising results specifically for this mutation. <br /><br />The researchers analyzed the molecular data of 863 Brazilian NSCLC patients, finding that 26% of them (220 patients) had KRAS mutations. Among the KRAS-mutated cases, the most common mutation was p.Gly12Cys, accounting for 35.5% of KRAS-mutated cases and 9% of all NSCLC cases (78 patients). Other KRAS variants identified were p.Gly12Val (23.6% of KRAS-mutated cases; 52 patients) and p.Gly12Asp (16.4% of KRAS-mutated cases; 36 patients). Overall, 25% of all reported Brazilian NSCLC cases (695 patients out of 2752) had KRAS mutations, with p.Gly12Cys being the most frequent variant, present in 9% of all Brazilian NSCLC cases (256 patients out of 2752). <br /><br />The findings suggest that nearly 10% of Brazilian NSCLC patients harbor the KRAS p.Gly12Cys mutation, potentially making them suitable candidates for the newly developed targeted therapy, Sotorasib. This study provides important insights into the prevalence of KRAS mutations in Brazilian NSCLC patients and highlights the potential benefits of personalized treatment options for this specific mutation.

Asset Subtitle

Rodrigo De Oliveira Cavagna

Meta Tag

Speaker Rodrigo De Oliveira Cavagna

Topic Targeted Therapies - KRAS

Keywords

Brazilian NSCLC patients

KRAS mutations

frequency

targeted therapies

p.Gly12Cys mutation

Sotorasib

molecular data

prevalence

personalized treatment

specific mutation